Trial Information
Phase 1 Study of Stereotactic Hypofractionated Radiosurgery of Low Grade Prostate Cancer/Early Stage
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate
- Gleason score ≤ 6 and low volume Gleason 7 (3+4)
- PSA < 10
- Clinical Stage of T2a or less
- Ability to understand and the willingness to sign a written informed consent
document
Exclusion Criteria:
- Prior radiation treatment for prostate cancer
- Gleason score > 7
- PSA > 10
- Clinical Stage of T2b or greater
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
PSA decline measured through laboratory testing.
Outcome Time Frame:
One month following radiosurgery through 5 year follow up
Safety Issue:
No
Principal Investigator
P. Brian Volpp, MD, MPH
Investigator Role:
Principal Investigator
Investigator Affiliation:
San Diego Radiosurgery/X-Ray Medical Group-Radiation Oncology
Authority:
United States: Institutional Review Board
Study ID:
SDRS0001
NCT ID:
NCT00969202
Start Date:
August 2009
Completion Date:
December 2014
Related Keywords:
- Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate
- Prostate Tumor
- Novalis Tx
- Novalis
- Stereotactic Radiosurgery
- Radiosurgery
- Radiation
- Prostatic Neoplasms
Name | Location |
San Diego Radiosurgery at Palomar Medical Center |
Escondido, California 92025 |